Incyte (INCY) Tops Q1 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Incyte (INCY) Tops Q1 EPS by 22c, Revenues Beat; Offers FY19 Revenue Guidance Below Consensus

Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs

April 30, 2019 7:00 AM EDT

Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the quarter ended March 31, 2019 Jakafi® (ruxolitinib) revenues of $376 million in Q1 2019 (+20% vs Q1 2018), reaffirming full year 2019 revenue guidance range of $1.58-1.65 billion Primary endpoint met in Phase 2 trial of ruxolitinib cream for the treatment of vitiligo; preparations now underway for Phase 3 development Decision taken to no longer participate in the co-funding of the development of baricitinib

Conference Call and... More